8 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 7 Phase 1, 6 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Terminated 1 |
| Phase 2 | 6 | Completed 4, Active not recruiting 1, Terminated 1 |
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow BDB001: new trials by email Literature Review of BDB001 trials Research Report on BDB001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BDB-001 Phase III Trial in ANCA-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Rituximab - ANCA Associated Vasculitis (AAV) | Phase 3 | Recruiting | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 300 | 2025-11-10 | 2026-08-13 |
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 93 | 2022-02-22 | 2025-08-07 |
| BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors BDB001 - Tumor, Solid | Phase 2 | Completed | Eikon Therapeutics | 1 | 2021-08-30 | 2025-11-12 |
| Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) BDB-001 Injection - Hidradenitis Suppurativa | Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 41 | 2021-08-18 | 2023-08-29 |
| Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) BDB-001 Injection, Placebo - Hidradenitis Suppurativa | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 50 | 2021-06-24 | 2024-03-26 |
| Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT - Solid Tumor, Adult, Pancreatic Cancer | Phase 2 | Active not recruiting | Institut Bergonié | 247 | 2021-03-31 | 2026-07-24 |
| Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS BDB-001 Injection, Conventional treatment - COVID-19 Pneumonia | Phase 2 / Phase 3 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 369 | 2020-07-23 | 2024-05-22 |
| Tolerability and Safety of BDB-001 Injection in Healthy Subjects BDB-001 injection, Placebo - Healthy | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 33 | 2020-03-12 | 2022-05-04 |
| A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients BDB-001 injection - COVID-19 | Phase 1 | Terminated | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 18 | 2020-02-21 | 2024-05-21 |
| BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab BDB001 (EIK1001), Atezolizumab - Tumor, Solid | Phase 1 | Completed | Eikon Therapeutics | 40 | 2019-11-21 | 2025-11-12 |
| Safety and Tolerability of BDB-001 Injection in Healthy Subjects BDB-001 injection, Placebo - Healthy | Phase 1 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 28 | 2019-09-25 | 2022-05-04 |
| BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab BDB001 (EIK1001), Pembrolizumab - Tumor, Solid | Phase 1 | Completed | Eikon Therapeutics | 87 | 2018-02-15 | 2025-11-12 |
Neoplasms (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · COVID-19 (2) · Hidradenitis Suppurativa (2) · Carcinoma, Non-Small-Cell Lung (1) · Melanoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Pneumonia (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
Staidson (Beijing) Biopharmaceuticals Co., Ltd (8) · Eikon Therapeutics (3) · Institut Bergonié (1)
China (8) · United States (3) · Bangladesh (1) · France (1) · India (1) · Indonesia (1) · Spain (1)
Harry Raftopoulos, MD (3) · Baoxi Wang, Master (2) · Minghui Zhao, M.D. (1) · Minghui Zhao, Postdoc (1) · Qing Mao, Ph.D (1)
2019 (1)